60 Degrees Pharmaceuticals, Inc. (SXTP)
SXTP Stock Price Chart
Explore 60 Degrees Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze SXTP price movements and trends.
SXTP Company Profile
Discover essential business fundamentals and corporate details for 60 Degrees Pharmaceuticals, Inc. (SXTP) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
12 Jul 2023
Employees
3.00
Website
https://www.60degreespharma.comCEO
Geoffrey Stuart Dow
Description
60 Degrees Pharmaceuticals, Inc. is a specialty pharmaceutical firm dedicated to developing and bringing to market therapies aimed at preventing and treating infectious diseases within the United States. The company currently offers Arakoda, an approved medication for malaria prophylaxis. Its pipeline includes several investigational drugs: Tafenoquine, in its 'Arakoda regimen' formulation, is undergoing Phase IIb clinical trials for potential use against COVID-19. Additionally, Tafenoquine is the subject of Phase IIA clinical studies for conditions such as babesiosis, fungal pneumonias, and candidiasis. Another candidate, Celgosivir, is being developed to address Zika, various respiratory viruses, and dengue fever. Further strengthening its development efforts, 60 Degrees Pharmaceuticals holds a patent license agreement with Tufts Medical Center, collaborating to advance Tafenoquine specifically for the treatment and prevention of babesiosis. The company was established in 2010 and maintains its corporate headquarters in Washington, D.C.
SXTP Financial Timeline
Browse a chronological timeline of 60 Degrees Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 12 Aug 2026
EPS estimate is -$0.74, while revenue estimate is $185.00k.
Earnings released on 15 May 2026
EPS came in at -$1.28 falling short of the estimated -$0.76 by -68.42%, while revenue for the quarter reached $230.00k , missing expectations by -47.13%.
Earnings released on 26 Mar 2026
EPS came in at -$1.69 surpassing the estimated -$2.28 by +25.88%, while revenue for the quarter reached $310.00k , missing expectations by -3.13%.
Stock split effective on 20 Jan 2026
Shares were split 1 : 4 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 13 Nov 2025
EPS came in at -$2.64 falling short of the estimated -$1.84 by -43.48%, while revenue for the quarter reached $437.60k , beating expectations by +118.80%.
Earnings released on 13 Aug 2025
EPS came in at -$1.25 falling short of the estimated -$1.24 by -0.81%, while revenue for the quarter reached $100.93k , missing expectations by -32.71%.
Earnings released on 15 May 2025
EPS came in at -$1.56 falling short of the estimated -$1.31 by -19.08%, while revenue for the quarter reached $163.55k , missing expectations by -45.48%.
Earnings released on 27 Mar 2025
EPS came in at -$14.20 falling short of the estimated -$4.01 by -254.11%, while revenue for the quarter reached $261.44k , beating expectations by +4.58%.
Stock split effective on 24 Feb 2025
Shares were split 1 : 5 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 14 Nov 2024
EPS came in at -$4.65 falling short of the estimated -$3.00 by -55.00%, while revenue for the quarter reached $135.29k , missing expectations by -45.88%.
Earnings released on 14 Aug 2024
EPS came in at -$21.15 falling short of the estimated -$19.80 by -6.82%, while revenue for the quarter reached $124.97k , beating expectations by +24.97%.
Stock split effective on 12 Aug 2024
Shares were split 1 : 12 , changing the number of shares outstanding and the price per share accordingly.
Earnings released on 15 May 2024
EPS came in at $1.80 surpassing the estimated -$9.60 by +118.75%, while revenue for the quarter reached $105.67k , missing expectations by -21.43%.
Earnings released on 1 Apr 2024
EPS came in at -$26.41 falling short of the estimated -$16.21 by -62.92%, while revenue for the quarter reached $42.71k , missing expectations by -43.06%.
Earnings released on 20 Nov 2023
EPS came in at -$18.01 falling short of the estimated -$15.61 by -15.37%, while revenue for the quarter reached $51.19k , missing expectations by -48.81%.
Earnings released on 25 Aug 2023
EPS came in at -$1.40 , while revenue for the quarter reached $59.53k .
Earnings released on 31 Mar 2023
EPS came in at -$1.87 , while revenue for the quarter reached $17.17k .
Earnings released on 31 Dec 2022
EPS came in at -$1.20 , while revenue for the quarter reached -$75.65k .
Earnings released on 30 Sept 2022
EPS came in at -$1.04 , while revenue for the quarter reached $168.19k .
Earnings released on 30 Jun 2022
EPS came in at -$1.54 , while revenue for the quarter reached $45.17k .
Earnings released on 31 Mar 2022
EPS came in at -$37.68 , while revenue for the quarter reached $47.02k .
Earnings released on 31 Dec 2021
EPS came in at -$0.94 , while revenue for the quarter reached $286.65k .
SXTP Stock Performance
Access detailed SXTP performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
